Kymera Investor Day Presentation Deck
E3
1
Proteome Editing with Targeted Protein Degradation
A Nobel Prize (2004) Inspired Technology
KYMERA
Disease-causing
Target Protein
Degrader
E2
Peptides from
Degraded Protein
Ubiquitin
3
Ubiquitin Proteasome
System (UPS)
Proteasome
2
©2021 KYMERA THERAPEUTICS, INC.
Targeted Small
Molecule
Protein Degraders
Ubiquitin
Chain
KYMERA R&D DAY - December 16th, 2021
●
Expanded Opportunities
Small molecule binds to E3 and target
protein to effect its degradation
Small Molecule only needs to "weakly"
bind to protein:
Not inhibit its function
Highly potent/catalytic:
Small amount of drug needed
Highly specific
Genetic-like knock-down effects
Advantage of small molecule
development:
Route of administration,
manufacturing
Agnostic to protein type and disease
PAGE 5View entire presentation